ERBB2 and breast cancer: This difference re-emphasizes that there are regional variations in prevalence, a concept further supported Al-Kuraya et al. who demonstrated that a markedly higher frequency of HER2 and MYC amplifications are seen in Saudi as compared to Swiss breast cancers [2].